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To evaluate the potential protective efficacy of a live recombinant human immunodeficiency virus type 1 (HIV-1) canarypox
vaccine candidate, two chimpanzees were immunized five times with ALVAC-HIV-1 vCP250, a recombinant canarypox virus
that expresses the HIV-1IIIB(LAI) gp120/TM, gag, and protease gene products. One month after the last booster inoculation,
the animals were challenged by intravenous injection of cell-associated virus in the form of peripheral blood mononuclear
cells from an HIV-1IIIB(LAI)-infected chimpanzee. One chimpanzee with a neutralizing antibody titer to HIV-1IIIB(LAI) of 128 at
the time of challenge was protected, whereas both the second animal, with a neutralizing antibody titer of 32, and a naive
control animal became infected. At 5 months after challenge, the protected chimpanzee and a third animal, previously
immunized with various HIV-1MN antigens, were given a booster inoculation. The two animals were challenged intravenously
5 weeks later with twenty 50% tissue culture infectious doses of cell-free HIV-1DH12 , a heterologous subtype B isolate.
Neither chimpanzee had neutralizing antibodies to HIV-1DH12 , and neither one was protected from infection with this isolate.
The immune responses elicited by vaccination against HIV-1IIIB(LAI) or HIV-1MN did not, therefore, protect the animals from
challenge with the heterologous cell-free HIV-1DH12 . q 1997 Academic Press
INTRODUCTION MATERIALS AND METHODS
AnimalsRecombinant canarypox virus vectors induce both hu-
moral and T-cell-mediated immunity against diverse Adult male chimpanzees (Pan troglodytes) were
pathogens in animals (Baxby et al., 1992; Taylor et al., housed at the Laboratory for Experimental Surgery in
1992). Furthermore, a recombinant canarypox–rabies G Primates (LEMSIP), New York University, in biosafety
protein virus proved to be safe and immunogenic in hu- level 2 facilities in accordance with institutional guide-
mans (Cadoz et al., 1992). In a recent study ALVAC–HIV- lines and standard practices for the containment of infec-
1 vCP125, a recombinant canarypox virus expressing the tious diseases and the humane care and use of chimpan-
gp160 env gene product of HIV-1MN , induced HIV-1-spe- zees in biomedical research (Moor-Jankowski and Maho-
cific neutralizing antibodies and cytotoxic T-lymphocyte ney, 1989). Before all procedures the chimpanzees were
responses in 90 and 40% of human volunteers, respec- anesthetized by intramuscular (im) injection of ketamine
tively, when combined with a subunit rgp160 vaccine in hydrochloride (10 mg/kg).
a prime-boost regimen (Pialoux et al., 1995). A similar
Study designregimen, however, failed to protect chimpanzees from a
heterologous challenge with cell-free HIV-1SF2 (Girard et Two naive chimpanzees (C-401 and C-451) were im-
al., 1995). A possible explanation for this failure was that munized via the im route with 4 1 108 plaque-forming
the dose [106.1 50% tissue culture infectious doses units (PFU) of ALVAC–HIV-1 vCP250, a recombinant ca-
(TCID50)] of canarypox virus used to immunize the chim- narypox virus that expresses not only the HIV-1IIIB(LAI)
panzees was too low. We report here on the immuniza- gp120 and the transmembrane segment from gp41
tion of chimpanzees with a higher dose of a recombinant (gp120/TM), but also the gag and protease gene prod-
canarypox–HIV-1 virus, followed by challenge with ho- ucts. The animals received a total of five doses of vCP250
mologous and heterologous HIV-1 strains. at Months 0, 1, 5, 9, and 11. No subunit booster inocula-
tions were given.
Challenge viruses1 To whom reprint requests should be addressed at Unite´ de Virolo-
gie Mole´culaire, Institut Pasteur, 25 rue de Dr. Roux, 75724 Paris Cedex
For preparation of the cell-associated HIV-1IIIB(LAI) chal-15, France. Fax: 33-1-40 61 30 45.
2 Present address: University of California, Davis, Davis, CA 95616. lenge stock, a chimpanzee (C-087) was inoculated via
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the intravenous (iv) route with 100 TCID50 of the NIH processed. The anti-gp120 antibody avidity index (AI)
was then calculated as described (Hedman et al., 1989;HIV-1IIIB(LAI) stock (Arthur et al., 1989). The animal became
readily infected and a peripheral blood mononuclear cell Clements et al., 1995) from the difference in optical den-
sity (OD) values at 405 nm in corresponding wells. The(PBMC) stock obtained 3 months after infection was used
to infect a second naive chimpanzee (C-435). This animal AI was determined over a range of serum dilutions in
order to control for variations in antibody concentration.also became infected as demonstrated by persistent iso-
lation of virus from its PBMCs (Fultz et al., 1992). At 4
CTL assaysmonths after inoculation, a stock of its PBMCs was pre-
pared, aliquoted, and cryopreserved. The titer of this CD8/-specific CTL responses in the animals were
stock is 30 infectious cells per 106 PBMCs. evaluated using a peptide-restimulation assay and autol-
DH12 is a clinical isolate that readily infects chimpan- ogous Epstein–Barr virus-transformed B-lymphoblastoid
zees and multiplies in their cells in vitro (Shibata et al., cell lines as target cells (Walker, 1993). PBMCs were
1995). A chimpanzee challenge stock of HIV-1DH12 was stimulated in vitro with pools of overlapping 20-mer pep-
obtained from Malcolm Martin and Alan Schultz at the tides corresponding to amino acids 30 to 510 in Env and
NIH. The chimpanzee infectious dose of this stock is 139 to 369 in p24gag of HIV-1SF2 ; culture medium was
between 6 and 16 TCID50 (Shibata et al., 1996). RPMI 1640 containing 10% fetal bovine serum, 5% human
interleukin-2 (IL-2) (Schiaparelli), 100 IU/ml rIL-2 (Cetus
Virus isolation and serology Corp.), antibiotics, and 10 mg/ml of each peptide. After 8
days in culture, CD8/ cells were purified using magnetic
The presence of virus in PBMCs was monitored by beads coated with anti-CD8 antibodies (Dynal, Lake Suc-
cocultivation of each animal’s PBMCs with phytohemag- cess, New York) and tested for cytolytic activity in a stan-
glutinin-stimulated human indicator PBMCs and periodic dard 51Cr release assay (Erickson et al., 1993) against
assays of culture supernatants for reverse transcriptase autologous target cells pulsed with the homologous pep-
activity (Fultz et al., 1986) or p24gag antigen (Hollinger et tide pool (10 mg/ml of each peptide). Control targets were
al., 1992). Freshly stimulated human PBMCs were added pulsed with a heterologous peptide pool.
every 10 days.
Serial twofold dilutions of serum samples were tested RESULTS AND DISCUSSION
for total anti-HIV-1 antibodies with a commercially
available enzyme immunoassay (EIA) kit (Diagnostics Two chimpanzees were immunized with ALVAC–HIV-
1 vCP250, a recombinant canarypox-HIV-1 virus express-Pasteur, Marnes-la-Coquette, France). Titers were de-
fined as the reciprocal of the last serum dilution to give ing the HIV-1IIIB(LAI) gp120/TM, gag, and protease gene
products. The animals were bled regularly and their im-an optical density reading above the cut-off recom-
mended by the manufacturer. Antibodies to HIV-1 strains mune responses to HIV-1 monitored. Anti-V3 IIIB(LAI) an-
tibody titers remained at low levels until after the fourthIIIB(LAI) and DH12 V3-loop peptides were also deter-
mined by EIA, as previously described (Girard et al., immunization (9 months) when an increase in titers was
observed in serum from C-401 (Table 1); C-451 had an1995). Western blot assays were done using a commer-
cially available kit (Sanofi Diagnostics Pasteur, Marnes- increase in anti-V3 antibody titers only after the fifth im-
munization at 11 months. Total anti-HIV-1 antibody titers,la-Coquette, France) and a serum dilution of 1:100. Neu-
tralizing antibodies to HIV-1IIIB(LAI) were measured using a however, remained at low levels (Fig. 1). WB assays done
at the time of challenge (12 months) demonstrated thatquantitative syncytium inhibition assay on CEM-SS cells
(Nara et al., 1987). although a good anti-p24gag antibody response was
seen in both immunized animals, p17gag antibodiesAnti-gp120 antibody titers and avidity were determined
using an EIA. Briefly, duplicate microtiter plates (Max- were observed only in C-401, and that the anti-Env re-
sponse was weak in both chimpanzees (Fig. 2; lanesisorp, Nunc) were coated with concanavalin A at 2.5 mg/
well for 1 hr at room temperature, after which they were BC, first challenge). Neutralizing antibodies to HIV-1IIIB(LAI)
were detected only after the fourth and fifth immuniza-washed with PBS containing 1% Tween 20 and coated
with 50 ng/well of rgp120 (British MRC AIDS Reagent tions for C-401and C-451, respectively (Table 2). No neu-
tralizing antibodies to a clinical isolate of HIV-1 (BZ167)Research Project), which was derived from a clinical iso-
late of HIV-1 (HIV-1GB8) (Farrar et al., 1991; Jones et al., were detected using a resting cell assay, as described
by Zolla-Pazner et al. (1995).1995). Sequential twofold dilutions of sera in PBS con-
taining 2% bovine serum albumin were added and incu- One month after the last booster inoculation, the immu-
nized animals and a naive control (C-353) were chal-bated for 2 hr at 377. Binding antibodies were detected by
standard methods with alkaline phosphatase-conjugated lenged via the iv route with 6 1 105 viable PBMCs (equiv-
alent to 20 infectious doses) from an HIV-1IIIB(LAI) infectedanti-human IgG and p-nitrophenyl phosphate substrate
using one of the duplicate plates, whereas the other plate chimpanzee (C-435). In three previous experiments, this
dose of cell-associated virus from the same stock ofwas first soaked with PBS containing 8 M urea and then
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TABLE 1 two- to fourfold higher than those of C-451 at time of
challenge (Fig. 1, Tables 1 and 2). The anti-canarypoxAnti-V3 Antibody Titers of Chimpanzees Immunized
antibody levels of C-401 and C-451 as determined by EIAwith ALVAC-HIV-1 vCP250
were 160 and 60 EIA units (EU)/ml, respectively, indicat-
Chimpanzees ing a strong immune response to the virus vector (a cut-
off value of 0.6 EU/ml is considered positive in human
C-401
volunteers). C-401 was, therefore, in all aspects, a betterC-451
responder than C-451 to the canarypox virus-HIV-1 vac-Monthsa V3-IIIB(LAI) V3-IIIB(LAI) V3-DH12
cine candidate. No CTL activity directed to either Env or
0 589 330 ND p24gag epitopes were, however, detected in either of the
6 710 2,100 NDb chimpanzees at any of the time points tested, including
9c 330 760 ND
the day of challenge. The lack of a CTL response follow-10 850 8,900 ND
ing five immunizations with a live recombinant canarypox11c 340 3,600 ND
virus is surprizing, but it should be noted that a significant12d 7900 22,000 ND
17c ND 8,800 6 CTL reponse, using a different recombinant canarypox–
18e ND 32,000 6 HIV-1 virus (vCP125), was seen in only 40% of human
19 ND 38,000 22 volunteers (Pialoux et al., 1995), while chimpanzees im-
20 ND 20,000 140
munized with this recombinant failed to develop a CTL21 ND 15,000 170
response (Girard et al., 1995). Another explanation for
a Months after first immunization. this lack of CTL activity might be that the assay was
b ND, not done. not sensitive enough. However, CTL activity could be
c Booster inoculation with vCP250. demonstrated in HIV-1SF2-infected chimpanzees, startingd Challenge with cell-associated HIV-1IIIB(LAI) . at 6–8 weeks postinoculation, using this assay methode Challenge with cell-free HIV-1DH12 .
(C Walker, personal communication).
After challenge, the chimpanzees were bled every 2
cryopreserved PBMCs, readily infected three of three na- weeks for 8 weeks and then at monthly intervals. PBMCs
ive chimpanzees (Fultz et al., 1992; Saksela et al., 1993, from the control animal and C-451 were initially virus
and unpublished data). The total anti-HIV-1, anti-V3 positive at 4 and 2 weeks after challenge, respectively.
Chimpanzee C-451 also showed a strong anamnesticIIIB(LAI), and neutralizing antibody titers of C-401 were
FIG. 1. Anti-HIV-1 antibody responses in chimpanzees. Animals C-451 and C-401 were immunized with ALVAC–HIV-1 vCP250 (open arrows) and
challenged with HIV-1IIIB(LAI) and/or HIV-1DH12 (closed arrows). Animals C-353 and C-573 were included as naive unimmunized controls. Antibody
titers were determined by EIA using serial twofold dilutions of chimpanzee serum samples; titers are defined as the last dilution of serum that gave
an OD reading above the cut-off value recommended by the manufacturer. C-451 (j, solid line); C-401 (l, dashed line); C-353 (m, dotted line); and
C-573 (l, solid line).
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FIG. 2. HIV-1 antigen-specific responses of chimpanzees at time of challenge (BC) and 8 weeks after challenge (AC). WB assays were performed
using a serum dilution of 1:100. First challenge: HIV-1IIIB(LAI) ; second challenge: HIV-1DH12 .
antibody response by both EIA (Fig. 1) and neutralizing negative during 5 months of follow-up, and its antibody
titers decreased slowly by all assays (Figs. 1 and 2, Tableantibody assays (Table 2). Consistent with these results,
2). Of interest was the finding that the neutralizing anti-WB analysis showed not only that bands representing
body titer of the unprotected animal (C-451) at time ofEnv and Gag antibody reactivity had intensified, but also
challenge was 32, whereas that of the protected animalthat novel serum reactivities had appeared (Fig. 2, lane
(C-401) was 128. Although no firm conclusions can beAC, first challenge). In contrast, C-401 remained virus
drawn from a study involving only two animals, this ob-
servation agrees with previous results that suggested
TABLE 2 an association between neutralizing antibody titers and
protection from HIV-1 infection in the chimpanzee modelHIV-1HIB(LAI) Neutralizing Antibody Titers
(Berman et al., 1990; Girard et al., 1991, 1995; Fultz et
Chimpanzees al., 1992; Bruck et al., 1994; Zolla-Pazner et al., 1996).
Similar results were obtained for HIV-2 (Putkonen et al.,
Monthsa C-451 C-401 1991a,b), while Van Rompay et al. (1996) demonstrated
that protection from oral SIV infection of neonatal ma-6 4 4
caques born from immunized mothers correlated with9b 0 0
10 4 32 the titers of neutralizing antibodies of the immunized fe-
11b 0 16 males. Furthermore, it was recently demonstrated that
12c 32 128 the protection from SIV infection conferred by live attenu-
13 512 64 ated SIVDnef vaccines is associated with the levels of14 512 32
high-avidity neutralizing antibodies in the immunized ani-18d NDe 64
mals (Wyand et al., 1996). This result also suggests that
a Neutralizing antibody titers were expressed as the reciprocal of the recombinant canarypox–HIV-1 viruses can induce pro-
dilution of serum that resulted in 90% reduction of the number of syncy- tective neutralizing antibody titers in some chimpanzees
tia formed on CEM-SS cells by HIV-1IIIB(LAI) (Nara et al., 1993). when used at a high dose in repeated immunizations.b Booster inoculation with vCP250.
After 5 months of follow-up, C-401 was again inocu-c Challenge with cell-associated HIV-1IIIB(LAI) .
lated im with 4 1 108 PFU of vCP250, and 1 month laterd Challenge with cell-free HIV-1DH12 .
e ND, not done. it was challenged with 20 TCID50 of cell-free HIV-1DH12
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TABLE 3
Lack of Correlation among Anti-gp120 Antibody Titers, Avidity of Antibodies to gp120, and Protection from Challenge
Anti-gp120 Avidity Challenge
Experiment Chimpanzee Immunogens titer a indexb virus Protection
1 C-451 vCP250 50 19 IIIB (cells) No
C-401 vCP250 100 23 IIIB (cells) Yes
2 C-401 vCP250 100 25 DH12 No
C-489 vCP205 / gp140 MN/LAI / V3-MN peptide 400 80 DH12 No
/ MN-T/B peptide
3c C-477 vCP125 / gp140 MN/LAI 800 91 SF2 No
C-641 vCP125 / gp140 MN/LAI 200 90 SF2 No
C-483 gp140 MN/LAI / V3 MN peptide 3200 96 SF2 Yes
C-323 gp140 MN/LAI / V3 MN peptide 1600 89 SF2 Yes
a Titers expressed as the reciprocal of the last serum dilution to give an OD reading of ⁄0.1 at 405 nm.
b Avidity index  (OD urea-treated well/OD untreated well) 1 100; All values 30% are considered to indicate low avidity antibody (Hedman et
al., 1989).
c Described in Girard et al. (1995).
(1 ml of a 1:400 dilution of the virus stock provided by demonstrated that three chimpanzees immunized with
recombinant gp120 MN were protected from heterolo-Malcolm Martin) together with a naive control (C-573).
The gp120 gene of HIV-1DH12 has only 80% homology with gous challenge with HIV-1SF2 . Sera from the protected
animals were unable to neutralize HIV-1SF2 infectivity forthat of HIV-1IIIB(LAI) (Shibata et al., 1996), making this a
heterologous intraclade challenge. Both C-401 and the PBMCs, but they did neutralize infectivity for AA5 cells
of a T-cell-line-adapted HIV-1SF2 variant. Since HIV-1SF2control animal readily became infected, as shown by
virus isolation from PBMCs at 2 weeks after challenge replicates poorly in chimpanzees (Girard et al., 1995), it
is possible that protection of chimpanzees from infectionand thereafter. C-401 developed a strong anamnestic
response to HIV-1 (Figs. 1 and 2), and infection of both with this virus is easier to achieve than it is from other
subtype B strains. This possibility is supported by theanimals elicited antibodies to a V3 peptide from HIV-
1DH12 (Table 1). At the times of the last vCP250 inoculation fact that chimpanzees infected with HIV-1SF2 could readily
be superinfected with HIV-1IIIB(LAI) or HIV-1DH12 (Fultz etand subsequent HIV-1DH12 challenge, a third animal (C-
489) was also included. This chimpanzee had been im- al., 1987; Fultz, 1995; Shibata et al., 1996). However, at
least one chimpanzee infected with HIV-1IIIB(LAI) was su-munized previously with a variety of HIV-1 immunogens,
including vCP205 (a recombinant canarypox virus ex- perinfected with HIV-1DH12 (Fultz, 1995). In contrast, Shi-
bata et al. (1996) could not demonstrate HIV-1DH12 super-pressing the env gp120 with transmembrane region, gag,
and protease genes of HIV-1MN), a HIV-1MN T- and B-cell infection of HIV-1IIIB(LAI)-infected chimpanzees. Consider-
able evidence suggests that the neutralization sensitivitychimeric peptide, recombinant gp140 MN/LAI, and a V3
MN peptide. Like C-401, chimpanzee C-489 was not pro- of primary isolates of HIV-1 differs from that of T-cell-
line-adapted viruses (Daar et al., 1990, Bou-Habib et al.,tected from HIV-1DH12 challenge; virus was isolated from
its PBMCs and its antibody titer to HIV-1 increased (not 1994, Hanson 1994). Antibodies directed to epitopes out-
side of the V3 loop are more important in the neutraliza-shown).
At time of challenge, C-489 had an anti-HIV-1MN neu- tion of primary isolates, while V3-targeted neutralizing
antibodies are important for neutralization of T-cell-line-tralizing antibody titer of 8, but no neutralizing antibodies
to HIV-1DH12 (not shown) as determined using a quantita- adapted strains (Vancott et al., 1995). The lack of neu-
tralizing antibodies could, therefore, be explained by thetive immunohistochemically based infectivity reduction
assay on PBMCs (Nara et al., in press). Similarly, C-401 fact that HIV-1DH12 is a primary isolate, whereas the
IIIB(LAI) strain is T-cell adapted.had an anti-HIV-1IIIB(LAI) neutralizing antibody titer of 64,
but no neutralizing antibodies to HIV-1DH12 . The lack of The presence of high-avidity anti-gp120 antibodies has
also been implicated as an important correlate for protec-protection from HIV-1DH12 challenge, therefore, was asso-
ciated with the absence of neutralizing antibodies to the tive antibody responses against HIV-1 and SIV infection
(Devash et al., 1990; Clements et al., 1995). The serachallenge virus. However, we previously showed that two
chimpanzees immunized with a recombinant gp140 MN/ from the immunized chimpanzees were, therefore, tested
for such antibodies by EIA. Sera from chimpanzees im-LAI molecule and V3 MN peptide were protected from a
heterologous intraclade challenge with HIV-1SF2 , despite munized with rgp140 MN/LAI combined with either a
recombinant canarypox virus expressing the gp120/TMthe absence of demonstrable neutralizing antibodies to
HIV-1SF2 (Girard et al., 1995). Berman et al. (1996) also of HIV-1MN (ALVAC-HIV-1 vCP125) or a V3 MN peptide
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heterologous infection with a primary isolate of human immunodefi-and then challenged with HIV-1SF2 (Girard et al., 1995)
ciency virus type 1. J. Infect. Dis. 173, 52–59.were also included in this experiment. The results dem-
Bou-Habib, D. C., Roderiquez, G., Oravecz, T., Berman, P. W., Lusso, P.,onstrated that the two chimpanzees immunized with and Norcross, M. A. (1994). Cryptic nature of envelope V3 region
vCP250 (C-401 and C-451) had low anti-gp120 antibody epitope protects primary monocytotropic human immunodeficiency
titers with low avidity, while the chimpanzees that had virus type 1 from antibody neutralization. J. Virol. 68, 6006–6013.
Bruck, C., Thiriart, C., Fabry, L., Francotte, M., Pala, P., van Opstal, O.,immunization regimens that included envelope subunits
Culp, J., Rosenberg, M., de Wilde, M., Heidt, P., and Heeney, J. (1994).had higher antibody titers with high avidity (Table 3).
HIV-1 envelope-elicited neutralizing antibody titers correlate with pro-However, no correlation between anti-gp120 antibody
tection and virus load in chimpanzees. Vaccine 12, 1141–1148.
avidity and protection from challenge was noted in any Cadoz, M., Strady, A., Meignier, B., Taylor, J., Tartaglia, J., Paoletti, E.,
of these chimpanzees. Although the HIV-1GB8 gp160 env and Plotkin, S. (1992). Immunization with canarypox virus expressing
rabies glycoprotein. Lancet 339, 1429–1432.gene shows only approximately 84% overall homology
Clements, J. E., Montelaro, C., Zink, M. C., Amedee, A. M., Miller, S.,with the gp160 env genes from IIIB(LAI), MN, and SF2,
Trichel, A. M., Jagerski, B., Hauer, D., Martin, L. N., Bohm, R. P., andVella et al. (1995) demonstrated that the rgp120 GB8
Murphey-Corb, M. (1995). Cross-protective immune responses in-
was recognized by all sera from HIV-1-infected patients duced in rhesus macaques by immunization with attenuated macro-
tested. Furthermore, hyperimmune sera raised against phage-tropic simian immunodeficiency virus. J. Virol. 69, 2737–2744.
rgp120 derived from HIV-1 strains IIIB(LAI), MN, SF2, or Daar, E. S., Li, X. L., Moudgil, T., and Ho, D. D. (1990). High concentra-
tions of recombinant soluble CD4 are required to neutralize primaryGB8 showed comparable recognition of the HIV-1GB8
human immunodeficiency virus type 1 isolates. Proc. Natl. Acad. Sci.gp120 by EIA.
USA 87, 6574–6578.Altogether, these results leave the question of immune
Devash, Y., Calvelli, T., Wood, D., Reagan, K., and Rubinstein, A. (1990).
correlates of protection from HIV-1 in the chimpanzee Vertical transmission of HIV-1 is correlated with the absence of high
model unanswered and suggest that intraclade cross- affinity/avidity maternal antibodies to the gp120 principal neutralizing
domain. Proc. Natl. Acad. Sci. USA 87, 3445–3449.protection among HIV-1 isolates will not be easily
Erickson, A. L., Houghton, M., Choo, Q. L., Weiner, A. J., Ralston, R.,achieved and might differ from isolate to isolate. The
Muchmore, E., and Walker, C. M. (1993). Hepatitis C virus-specificinduction of antibodies with broad spectrum neutralizing
CTL responses in the liver of chimpanzees with acute and chronic
activity against multiple primary isolates remains at this hepatitis C. J. Immunol. 151, 4189–4199.
time one of the major goals in the development of an Farrar, G. H., Roff, M. A., Amin, T., Ball, J., Parret, A. M., Battacharayya,
efficacious HIV-1 vaccine. U., Booth, J., Wansbrough-Jones, M. H., and Greenaway, P. J. (1991).
Characterization of a series of human immunodeficiency virus iso-
lates derived sequentially from a single patient. J. Med. Virol. 34,
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